| 贾 南,张东平,胡海燕,吴新婷,贾 毅,卞伟妮.茵栀黄口服液联合熊去氧胆酸胶囊治疗胆汁淤积性黄疸的临床研究[J].,2019,19(20):3886-3889 |
| 茵栀黄口服液联合熊去氧胆酸胶囊治疗胆汁淤积性黄疸的临床研究 |
| A Clinical Study on Yinzhihuang Oral Liquid combined with Ursodeoxycholic Acid Capsule in the Treatment of Cholestasis Jaundice |
| 投稿时间：2019-02-23 修订日期：2019-03-18 |
| DOI：10.13241/j.cnki.pmb.2019.20.019 |
| 中文关键词: 茵栀黄口服液 熊去氧胆酸 胆汁淤积性黄疸 |
| 英文关键词: Yinzhihuang oral liquid Ursodeoxycholic acid Cholestasis jaundice |
| 基金项目:陕西省重点研发计划项目（ 2019SF-051）；西安医学院第二附属医院2016年院级课题(16KY0122) |
|
| 摘要点击次数: 930 |
| 全文下载次数: 677 |
| 中文摘要: |
| 摘要 目的：探讨茵栀黄口服液联合熊去氧胆酸胶囊治疗胆汁淤积性黄疸的临床疗效和安全性。方法：选择2016年9月-2018年3月我院收治的胆汁淤积性黄疸儿童94例，按随机抽签方式分为对照组及观察组，每组47例。对照组给予熊去氧胆酸胶囊治疗，观察组在对照组基础上给予茵栀黄口服液治疗，比较两组患儿治疗前后血清胆红素水平、肝功能及免疫指标水平的变化及不良反应的发生情况。结果：治疗后，两组总胆红素(Total Bilirubin，TBil)、直接胆红素(Direct Bilirubin，DBil)、谷丙转氨酶(Alanine transaminase，ALT)、谷草转氨酶(Aspartate aminotransferase，AST)、碱性磷酸酶(Alkaline phosphatase，ALP)、谷氨酰转肽酶(Glutamyl transpeptidase，GGT)、CD8+水平均较治疗前显著下降(P＜0.05)，且观察组TBil、DBil、ALT、AST、ALP、GGT、CD8+水平均显著低于对照组[(86.29±11.07)μmol/L vs. (132.75±16.53)μmol/L、(53.47±6.71)μmol/L vs. (86.72±9.09)μmol/L、(76.53±8.60) U/L vs. (127.05±11.79) U/L、(138.59±12.14) U/L vs. (160.08±15.82) U/L、(206.88±79.04) U/L vs. (270.40±68.19) U/L、(223.04±89.59) U/L vs. (280.62±96.17) U/L、(22.80±3.79)% vs. (26.52±4.30)%](P＜0.05)。治疗后，两组CD4+、CD4+/CD8+均较治疗前显著上升(P＜0.05)，且观察组CD4+、CD4+/CD8+ [(38.91±7.20)%、(1.69±0.55)]均显著高于对照组[(34.67±6.26)%、(1.31±0.49)](P＜0.05)。治疗期间，两组患儿均没有出现相关不良反应。结论：茵栀黄口服液联合熊去氧胆酸胶囊治疗胆汁淤积性黄疸患儿可有效改善其胆红素水平及肝功能，且具有一定的免疫调节作用。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the clinical efficacy and safety of Yinzhihuang oral liquid combined with ursodeoxycholic acid capsule in the treatment of cholestasis jaundice. Methods: Ninety-four children with cholestasis jaundice admitted to our hospital from September 2016 to March 2018 were selected and randomly divided into control group (47 cases) and observation group (47 cases). The control group was treated with ursodeoxycholic acid capsule, while the observation group was treated with Yinzhihuang oral liquid on the basis of the control group. The changes of serum bilirubin, liver function and immune indexes and the occurrence of adverse reactions were compared between the two groups before and after treatment. Results: After treatment, the levels of total bilirubin (TBil), direct bilirubin (DBil), alanine transaminase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), glutamyl transpeptidase (GGT) and CD8+ in both groups were significantly lower than those before treatment (P<0.05), and the levels of TBil, DBil, ALT, AST, ALP, GGT and CD8+ in the observation group were significantly lower than those in the control group[(86.29±11.07)μmol/L vs. (132.75±16.53)μmol/L, (53.47±6.71)μmol/L vs. (86.72±9.09)μmol/L, (76.53±8.60) U/L vs. (127.05±11.79) U/L, (138.59±12.14) U/L vs. (160.08±15.82) U/L, (206.88±79.04) U/L vs. (270.40±68.19) U/L, (223.04±89.59) U/L vs. (280.62±96.17) U/L, (22.80±3.79)% vs. (26.52±4.30)%](P<0.05). After treatment, the levels of CD4+, CD4+/CD8+ in both groups were significantly higher than those before treatment (P<0.05), and the levels of CD4+, CD4+/CD8+ [(38.91 +7.20)%, (1.69 +0.55)] in the observation group were significantly higher than those in the control group [(34.67 +6.26)%, (1.31 +0.49)] (P<0.05). During the treatment period, there were no related adverse reactions in both groups. Conclusion: Yinzhihuang oral liquid combined with ursodeoxycholic acid capsule can effectively improve the bilirubin level and liver function of children with cholestasis jaundice, and has certain immunoregulatory effect. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
